MedTrace Logo

Immune Response to the COVID-19 Vaccine

NCT04936997 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-20

No results posted yet for this study

Summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Conditions

  • Covid19
  • Cancer
  • Malignancy
  • Vaccine Response Impaired

Interventions

BIOLOGICAL

SARS-COV2 Pfizer Vaccine

Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Rachna Shroff, MD · University of Arizona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2021-08-25
Completion
2022-05-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04936997 on ClinicalTrials.gov